- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Esperion Therapeutics and Galmed Pharmaceuticals Compared
Analyzing the strengths and weaknesses of these two small-cap medical companies
Mar. 22, 2026 at 8:38am
Got story updates? Submit your updates here. ›
Galmed Pharmaceuticals (NASDAQ:GLMD) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap pharmaceutical companies, but which one is the better investment? This article compares the two companies across key metrics like analyst ratings, institutional ownership, financials, and valuation.
Why it matters
Investors looking to gain exposure to the pharmaceutical sector may be considering these two small-cap companies. Understanding how they compare on important factors can help inform investment decisions and identify the stronger long-term opportunity.
The details
The analysis found that Esperion Therapeutics has a stronger consensus rating from analysts and higher potential upside, despite Galmed Pharmaceuticals having higher earnings. Esperion also has lower price-to-earnings and more institutional ownership, indicating it may be the more attractive investment at this time.
- The analysis was published on March 22, 2026.
The players
Galmed Pharmaceuticals
A biopharmaceutical company focused on developing treatments for liver diseases, including its lead drug candidate Aramchol for non-alcoholic steatohepatitis (NASH).
Esperion Therapeutics
A pharmaceutical company that develops and commercializes medicines for the treatment of elevated low-density lipoprotein (LDL) cholesterol, including its marketed products NEXLETOL and NEXLIZET.
The takeaway
Based on the analysis, Esperion Therapeutics appears to be the stronger investment opportunity compared to Galmed Pharmaceuticals, with a more favorable analyst consensus, higher institutional ownership, and more affordable valuation despite Galmed's higher earnings.
